Annals of Internal Medicine,
NEW: A phase 2 study from Gilead Sciences and Merck finds that once-weekly oral islatravir plus lenacapavir (ISL+LEN…
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Overview of attention for article published in Annals of Internal Medicine, December 2025
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (97th percentile)
-
High Attention Score compared to outputs of the same age and source (80th percentile)
Mentioned by
- news
- 5 news outlets
- 9 X users
- 1 Facebook page
- 1 Redditor
- bluesky
- 5 Bluesky users
- podcasts
- 1 podcast
Readers on
- mendeley
- 10 Mendeley